Cell growth of ovarian cancer cells is stimulated by xenoestrogens through an estrogen-dependent pathway, but their stimulation of cell growth appears not to be involved in the activation of the mitogen-activated protein kinases ERK-1 and p38

Journal of Reproduction and Development

Volumn 55, Issue 1, 2009, Pages 23-29

  Park, Se Hyung ^a   Kim, Ki Yon ^a   An, Beum Soo ^a   Choi, Jung Hye ^a   Jeung, Eui Bae ^b   Leung, Peter C K ^a   Choi, Kyung Chul ^a,b  

^a CHILDREN S AND WOMEN S HEALTH CENTRE OF BRITISH COLUMBIA   (Canada)

^b Chungbuk National University   (South Korea)

Author keywords

Endocrine disrupting chemical; Estrogen receptor; Estrogen response element; Extracellular signalregulated kinase; Mitogen activated protein kinase

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; ENDOCRINE DISRUPTOR; ENZYME INHIBITOR; ESTROGEN; ESTROGEN RECEPTOR; FLAVONOID; IMIDAZOLE DERIVATIVE; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE P38; PYRIDINE DERIVATIVE;

ARTICLE; CELL GROWTH; DNA RESPONSIVE ELEMENT; DRUG ANTAGONISM; DRUG EFFECT; ENZYME ACTIVATION; FEMALE; GENE EXPRESSION REGULATION; GENETICS; HUMAN; METABOLISM; OVARY TUMOR; PATHOLOGY; PHYSIOLOGY; SIGNAL TRANSDUCTION; TUMOR CELL CULTURE;

CELL GROWTH PROCESSES; ENDOCRINE DISRUPTORS; ENZYME ACTIVATION; ENZYME INHIBITORS; ESTROGENS; FEMALE; FLAVONOIDS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMIDAZOLES; MITOGEN-ACTIVATED PROTEIN KINASE 3; OVARIAN NEOPLASMS; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PYRIDINES; RECEPTORS, ESTROGEN; RESPONSE ELEMENTS; SIGNAL TRANSDUCTION; TUMOR CELLS, CULTURED;

EID: 65349088088     PISSN: 09168818     EISSN: 13484400     Source Type: Journal    
DOI: 10.1262/jrd.20094     Document Type: Article

References (40)

1. Schally AV, Comaru-Schally AM, Nagy A, Kovacs M, Szepeshazi K, Plonowski A, Varga JL, Halmos G. Hypothalamic hormones and cancer. Front Neuroendocrinol 2001; 22: 248-291.
2. Cramer DW, Welch WR. Determinants of ovarian cancer risk. II. Inferences regarding pathogenesis. J Natl Cancer Inst 1983; 71: 717-721.
3. Bencko V. Human exposure to endocrine disrupters: carcinogenic risk assessment. Folia Histochem Cytobiol 2001; 39 (Suppl 2): 24-25.
4. Brevini TA, Zanetto SB, Cillo F. Effects of endocrine disruptors on developmental and reproductive functions. Curr Drug Targets Immune Endocr Metabol Disord 2005; 5: 1-10.
5. Iguchi T, Watanabe H, Katsu Y. Application of ecotoxicogenomics for studying endocrine disruption in vertebrates and invertebrates. Environ Health Perspect 2006; 114 (Suppl 1): 101-105.
6. Daston GP, Cook JC, Kavlock RJ. Uncertainties for endocrine disrupters: our view on progress. Toxicol Sci 2003; 74: 245-252.
7. Yurino H, Ishikawa S, Sato T, Akadegawa K, Ito T, Ueha S, Inadera H, Matsushima K. Endocrine disruptors (environmental estrogens) enhance autoantibody production by B1 cells. Toxicol Sci 2004; 81: 139-147.
8. Colborn T, vom Saal FS, Soto AM. Developmental effects of endocrine-disrupting chemicals in wildlife and humans. Environ Health Perspect 1993; 101: 378-384.
9. Maffini MV, Rubin BS, Sonnenschein C, Soto AM. Endocrine disruptors and reproductive health: the case of bisphenol-A. Mol Cell Endocrinol 2006; 254-255: 179-186.
10. 2+ fluxes and prolactin release in GH3/B6 pituitary tumor cells. Environ Health Perspect 2005; 113: 431-439.
11. Markey CM, Rubin BS, Soto AM, Sonnenschein C. Endocrine disruptors: from Wingspread to environmental developmental biology. J Steroid Biochem Mol Biol 2002; 83: 235-244.
12. Staples CA, Dorn PB, Klecka GM, O'Block ST, Branson DR, Harris LR. Bisphenol A concentrations in receiving waters near US manufacturing and processing facilities. Chemosphere 2000; 40: 521-525.
13. Steinmetz R, Mitchner NA, Grant A, Allen DL, Bigsby RM, Ben-Jonathan N. The xenoestrogen bisphenol A induces growth, differentiation, and c-fos gene expression in the female reproductive tract. Endocrinology 1998; 139: 2741-2747.
14. Ghosh D, Taylor JA, Green JA, Lubahn DB. Methoxychlor stimulates estrogen-responsive messenger ribonucleic acids in mouse uterus through a non-estrogen receptor (non-ER) alpha and non-ER beta mechanism. Endocrinology 1999; 140: 3526-3533.
15. Vazquez-Duhalt R, Ayala M, Marquez-Rocha FJ. Biocatalytic chlorination of aromatic hydrocarbons by chloroperoxidase of Caldariomyces fumago. Phytochemistry 2001; 58: 929-933.
16. Nimrod AC, Benson WH. Environmental estrogenic effects of alkylphenol ethoxylates. Crit Rev Toxicol 1996; 26: 335-364.
17. Isidori M, Lavorgna M, Nardelli A, Parrella A. Toxicity on crustaceans and endocrine disrupting activity on Saccharomyces cerevisiae of eight alkylphenols. Chemosphere 2006; 64: 135-143.
18. Saito I, Onuki A, Seto H. Indoor air pollution by alkylphenols in Tokyo. Indoor Air 2004; 14: 325-332.
19. Kuch HM, Ballschmiter K. Determination of endocrine-disrupting phenolic compounds and estrogens in surface and drinking water by HRGC-(NCI)-MS in the picogram per liter range. Environ Sci Technol 2001; 35: 3201-3206.
20. Cheng CK, Chow BK, Leung PC. An activator protein 1-like motif mediates 17beta-estradiol repression of gonadotropin-releasing hormone receptor promoter via an estrogen receptor alpha-dependent mechanism in ovarian and breast cancer cells. Mol Endocrinol 2003; 17: 2613-2629.
21. Kim KY, Choi KC, Auersperg N, Leung PC. Mechanism of gonadotropin-releasing hormone (GnRH)-I and -II-induced cell growth inhibition in ovarian cancer cells: role of the GnRH-I receptor and protein kinase C pathway. Endocr Relat Cancer 2006; 13: 211-220.
22. Geisinger KR, Kute TE, Pettenati MJ, Welander CE, Dennard Y, Collins LA, Berens ME. Characterization of a human ovarian carcinoma cell line with estrogen and progesterone receptors. Cancer 1989; 63: 280-288.
23. Waring RH, Harris RM. Endocrine disrupters: a human risk? Mol Cell Endocrinol 2005; 244: 2-9.
24. Cunat S, Hoffmann P, Pujol P. Estrogens and epithelial ovarian cancer. Gynecol Oncol 2004; 94: 25-32.
25. Giacalone PL, Daures JP, Ouafik L, Martin PM, Laffargue F, Maudelonde T. Steroids and adrenomedullin growth patterns in human ovarian cancer cells: estrogenic-regulation assay. Gynecol Oncol 2003; 91: 651-656.
26. Schmitt E, Dekant W, Stopper H. Assaying the estrogenicity of phytoestrogens in cells of different estrogen sensitive tissues. Toxicol In Vitro 2001; 15: 433-439.
27. Mueller SO, Kling M, Arifin Firzani P, Mecky A, Duranti E, Shields-Botella J, Delansorne R, Broschard T, Kramer PJ. Activation of estrogen receptor alpha and ERbeta by 4-methylbenzylidene-camphor in human and rat cells: comparison with phyto- and xenoestrogens. Toxicol Lett 2003; 142: 89-101.
28. Choi KC, Jeung EB. The biomarker and endocrine disruptors in mammals. J Reprod Dev 2003; 49: 337-345.
29. Mosselman S, Polman J, Dijkema R. ER beta: identification and characterization of a novel human estrogen receptor. FEBS Lett 1996; 392: 49-53.
30. Ropero AB, Alonso-Magdalena P, Ripoll C, Fuentes E, Nadal A. Rapid endocrine disruption: environmental estrogen actions triggered outside the nucleus. J Steroid Biochem Mol Biol 2006; 102: 163-169.
31. Harris RM, Kirk CJ, Waring RH. Non-genomic effects of endocrine disrupters: inhibition of estrogen sulfotransferase by phenols and chlorinated phenols. Mol Cell Endocrinol 2005; 244: 72-74.
32. Edwards DP. Regulation of signal transduction pathways by estrogen and progesterone. Annu Rev Physiol 2005; 67: 335-376.
33. Albanito L, Madeo A, Lappano R, Vivacqua A, Rago V, Carpino A, Oprea TI, Prossnitz ER, Musti AM, Ando S, Maggiolini M. G protein-coupled receptor 30 (GPR30) mediates gene expression changes and growth response to 17beta-estradiol and selective GPR30 ligand G-1 in ovarian cancer cells. Cancer Res 2007; 67: 1859-1866.
34. Couse JF, Lindzey J, Grandien K, Gustafsson JA, Korach KS. Tissue distribution and quantitative analysis of estrogen receptor-alpha (ERalpha) and estrogen receptor-beta (ERbeta) messenger ribonucleic acid in the wild-type and ERalpha-knockout mouse. Endocrinology 1997; 138: 4613-4621.
35. Paech K, Webb P, Kuiper GG, Nilsson S, Gustafsson J, Kushner PJ, Scanlan TS. Differential ligand activation of estrogen receptors ERalpha and ERbeta at AP1 sites. Science 1997; 277: 1508-1510.
36. Pujol P, Rey JM, Nirde P, Roger P, Gastaldi M, Laffargue F, Rochefort H, Maudelonde T. Differential expression of estrogen receptor-alpha and -beta messenger RNAs as a potential marker of ovarian carcinogenesis. Cancer Res 1998; 58: 5367-5373.
37. Treeck O, Pfeiler G, Mitter D, Lattrich C, Piendl G, Ortmann O. Estrogen receptor {beta}1 exerts antitumoral effects on SK-OV-3 ovarian cancer cells. J Endocrinol 2007; 193: 421-433.
38. Dang VH, Choi KC, Jeung EB. Tetrabromodiphenyl ether (BDE 47) evokes estrogenicity and calbindin-D9k expression through an estrogen receptor-mediated pathway in the uterus of immature rats. Toxicol Sci 2007; 97: 504-511.
39. Cobb MH, Goldsmith EJ. How MAP kinases are regulated. J Biol Chem 1995; 270: 14843-14846.
40. Seval Y, Cakmak H, Kayisli UA, Arici A. Estrogen-mediated regulation of p38 mitogen-activated protein kinase in human endometrium. J Clin Endocrinol Metab 2006; 91: 2349-2357.